文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

白细胞介素-6轨迹与机械通气COVID-19 ARDS患者接受IL-6受体阻滞剂后的继发感染

Interleukin-6 Trajectory and Secondary Infections in Mechanically Ventilated Patients With Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Treated With Interleukin-6 Receptor Blocker.
PubMed 文献 · Crit Care Explor · 2021-02-03
一句话结论机械通气COVID-19肺炎患者IL-6在第7天达峰,托珠单抗组各时点IL-6更高且感染风险有增加趋势,非幸存者IL-6持续上升。

该回顾性队列纳入2020年3月12日至4月21日Washington University-Barnes Jewish Hospital ICU连续43例需机械通气的COVID-19呼吸衰竭患者,由主管医师酌情对符合细胞因子释放综合征临床 picture 者使用托珠单抗。IL-6于第0、3、7、14、21天检测,两组均在第7天达峰,托珠单抗组各时点IL-6均高于标准治疗组;托珠单抗使用与感染风险增加呈趋势相关。非幸存者IL-6持续上升,幸存者上升后下降。

要点

  • 机械通气COVID-19肺炎患者IL-6在第7天达峰,托珠单抗组与标准治疗组轨迹相似但托珠单抗组各时点IL-6更高。
  • 托珠单抗由主管医师酌情用于临床符合细胞因子释放综合征者,其使用与感染风险增加呈趋势相关(原文未给具体效应量)。
  • 非幸存者IL-6持续上升,幸存者IL-6上升后下降,提示IL-6轨迹或有助于风险分层。
  • 基线中位PaO2/FiO2 171.5(122-221),30.2%需血管升压药,APACHE-II 11(9-15)。
  • 研究为单中心回顾性队列,样本43例,托珠单抗非随机分配,结论需前瞻性验证。

适用人群与场景

  • 2020年3月12日至4月21日Washington University-Barnes Jewish Hospital医疗ICU连续收治、需机械通气的COVID-19呼吸衰竭患者,共43例。
  • 托珠单抗由主管医师酌情用于临床 picture 符合细胞因子释放综合征的患者,非随机分配。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 托珠单抗(IL-6受体阻滞剂)由主管医师酌情用于临床符合细胞因子释放综合征的机械通气COVID-19患者,原文未提及具体剂量、途径、频次或疗程。
  • IL-6在入ICU第0、3、7、14、21天检测,两组均在第7天达峰。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 基线中位PaO2/FiO2 171.5(122-221),13例(30.2%)需血管升压药;CRP 142.7(97.7-213.7),D-二聚体1,621(559-13,434),APACHE-II 11(9-15)。
  • 入院IL-6中位61 pg/mL(IQR 28.6-439 pg/mL);托珠单抗组在第0、3、7、14、21天IL-6均高于标准治疗组,两组均在第7天达峰。
  • 非幸存者IL-6持续上升,幸存者IL-6上升后下降。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究;原文未给出证据等级或推荐强度。
  • 局限:样本量小(43例)、单中心、回顾性、托珠单抗非随机分配(由主管医师酌情使用),感染风险增加仅为趋势相关,需前瞻性验证。

对床旁实践的改变

  • 对机械通气COVID-19肺炎患者,IL-6在第7天达峰,连续监测IL-6轨迹(第0、3、7、14、21天)或有助于识别非幸存者(IL-6持续上升)与幸存者(上升后下降)。
  • 使用托珠单抗者各时点IL-6更高,且感染风险有增加趋势,临床应警惕继发感染;但原文未给具体感染率或推荐预防措施。
  • 该研究为单中心回顾性小样本,托珠单抗非随机分配,不能据此改变托珠单抗的适用人群或推荐剂量。

指南或共识出处

  • Crit Care Explor(原文未提及具体指南或共识名称)

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: To describe the infectious complications and interleukin-6 trajectories in mechanically ventilated patients with coronavirus disease 2019.

DESIGN: Retrospective cohort study.

SETTING: ICUs at Washington University-Barnes Jewish Hospital in St. Louis, MO.

PARTICIPANTS: All consecutive patients admitted to the medical ICU and requiring mechanical ventilation from March 12, 2020, to April 21, 2020, were included.

INTERVENTIONS: Tocilizumab, an interleukin-6 receptor blocker, was prescribed at the discretion of the treating physicians to patients with a clinical picture compatible with cytokine release syndrome.

MEASUREMENTS: All the patients were followed to death or hospital discharge. Demographic and laboratory data were collected retrospectively from the electronic medical record. Interleukin-6 levels were measured at days 0, 3, 7, 14, and 21. Infections were divided into culture positive and culture negative (clinically suspected and treated). The main outcomes were infectious complications and interleukin-6 levels at different points in time.

RESULTS: Forty-three patients with respiratory failure secondary to coronavirus disease 2019 were on mechanical ventilation during the study period. Twenty-seven (68%) were male, and 31 (72.1%) were African-American. Median Charlson score was 2 (interquartile range, 0-4). Median Pao2/Fio2 was 171.5 (122-221) on the day of mechanical ventilation initiation, and 13 patients (30.2%) required vasopressors. C-reactive protein was 142.7 (97.7-213.7), d-dimer 1,621 (559-13,434), and Acute Physiology and Chronic Health Evaluation-II 11 (9-15). Interleukin-6 levels at admission were 61 pg/mL (interquartile range, 28.6-439 pg/mL). Patients treated with tocilizumab had higher levels of interleukin-6 at each measurement (days 0, 3, 7, 14, and 21) compared with patients receiving standard of care. Both groups reached peak interleukin-6 levels at day 7. Administration of tocilizumab was associated with a trend toward increased risk of infection.

CONCLUSIONS: Interleukin-6 levels peak at day 7 in patients with severe coronavirus disease 2019 pneumonia requiring mechanical ventilation and follows a similar trajectory in patients with coronavirus disease 2019 pneumonia requiring mechanical ventilation irrespective of treatment with interleukin-6R blockers. Interleukin-6 levels continued to rise in nonsurvivors, in comparison with survivors, where the rise in interleukin-6 levels was followed by a decline.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Vazquez Guillamet MC, Kulkarni HS, Montes K, et al. Interleukin-6 Trajectory and Secondary Infections in Mechanically Ventilated Patients With Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Treated With Interleukin-6 Receptor Blocker. Crit Care Explor. 2021. PMID: 33554125. doi:10.1097/CCE.0000000000000343

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。